Peter Libby

Clinical researcher
Mass General Brigham / Harvard Medical School -

Latest contributions

All you need to know - Intracoronary imaging for vulnerable plaque

22 May 2026 – From EuroPCR 2026

This session provides a comprehensive overview of vulnerable plaque pathophysiology and the role of intracoronary imaging in its identification. It assesses treatment options, including the potential role of preventative PCI and intensive medical therapy, to guide clinical decision-making in managing plaque vulnerability.

All you need to know - Intracoronary imaging for vulnerable plaque

Rethinking coronary artery disease: from ischaemia to atheroma - Implications of the Lancet Commission for Interventional Cardiology

20 May 2026 – From EuroPCR 2026

This session invites a re-evaluation of coronary artery disease by shifting focus from ischemia to atheroma, integrating insights from the Lancet Commission for Interventional Cardiology. It explores the significance of plaque burden, biology, and inflammation in guiding PCI decisions and outlines the future role of PCI...

All we need to know about vulnerable plaque

19 May 2026 – From EuroPCR 2026

Understand the critical importance of vulnerable plaque identification and management. This session covers optimal strategies for detecting vulnerable plaques, their prognostic implications, and evidence-based treatment approaches illustrated through detailed case presentations.

All we need to know about vulnerable plaque

Why are most unstable coronary lesions missed by angiography?

20 May 2026 – From EuroPCR 2026

Inflammation is increasingly recognised as a key driver of residual cardiovascular risk and plaque instability in coronary artery disease. Yet many vulnerable plaques remain difficult to identify using conventional angiography, often appearing as non-obstructive lesions despite their potential to cause acute coronary events.

In this interview, Davide...

Why angiography misses unstable coronary lesions